Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Narrated by Peter Capaldi, produced by David Paterson, directed by David Malone, made by Boa Picture Company, with the Discovery Channel 22 September Killer Earth, about the disappearance of dinosaurs; 65 million years ago, two-thirds of species disappeared; French geophysicist Vincent Courtillot; flood basalt eruptions; the Kīlauea volcano, in the Pacific Ocean, is the world's most active volcano; volcanologist Sir Stephen Sparks of the University of Bristol; the Latourell Falls in Oregon; volcanologist Stephen Self; geochronologist Paul Renne of the Berkeley Geochronology Center, and his research on the Siberian Traps, which erupted 250 million years ago, when 95% of species disappeared in the Permian-Triassic extinction event (P-T boundary); sedimentologist Tom Yancey. Narrated by Heather Couper, produced by Stuart Carter, directed by David Hutt, made by Pioneer Productions.
the number of electrons surrounding the molecule, which increases with the alkane's molecular weight the surface area of the molecule Under standard conditions, from CH4 to C4H10 alkanes are gaseous; from C5H12 to C17H36 they are liquids; and after C18H38 they are solids. As the boiling point of alkanes is primarily determined by weight, it should not be a surprise that the boiling point has an almost linear relationship with the size (molecular weight) of the molecule. As a rule of thumb, the boiling point rises 20–30 °C for each carbon added to the chain; this rule applies to other homologous series. A straight-chain alkane will have a boiling point higher than a branched-chain alkane due to the greater surface area in contact, and thus greater van der Waals forces, between adjacent molecules. For example, compare isobutane (2-methylpropane) and n-butane, which boil at −12 and 0 °C, and 2,2-dimethylbutane and 2,3-dimethylbutane which boil at 50 and 58 °C, respectively. On the other hand, cycloalkanes tend to have higher boiling points than their linear counterparts due to the locked conformations of the molecules, which give a plane of intermolecular contact.
== Politics == Manmohan Singh (1933–2024), former Prime Minister of India from 2004 to 2014 Ajit Pal Singh Kohli, Indian politician and MLA from Patiala Assembly constituency Amolak Rattan Kohli (born 1942), former governor of the Indian state of Mizoram from 2001 to 2006 Om Prakash Kohli (1935–2023), former governor of the Indian state of Gujarat from 2014 to 2019 Abdul Ghani Kohli (born 1943), Indian J&K politician Mohammad Aslam Kohli, Indian J&K politician Krishna Kohli (born 1979), Pakistani politician (While her name is spelled as Kohli, she originates from the Koli people, who are unrelated to the Kohlis of the Khukhrain clan) Kuli Kohli (born 1970), Indian-British poet, writer, disabled activist and local council member Veeru Kohli (1964–2023), Pakistani human rights activist (While her name is spelled as Kohli, she originates from the Koli people, who are unrelated to the Kohlis of the Khukhrain clan)
Sources: en.wikipedia.org
=== SICRIT imaging === The Soft Ionization by Chemical Reaction in Transfer (SICRIT) source can be coupled with imaging techniques such as Atmospheric pressure (AP)-MALDI or laser ablation. In AP-MALDI + SICRIT configurations, SICRIT serves as an ambient-pressure post-ionization unit, increasing ion yield and extending molecular coverage, particularly for small metabolites and lipids. When combined with laser ablation, SICRIT enables soft ionization of ablated neutrals without matrix application, maintaining high spatial resolution down to ~1 μm. Recent studies demonstrate that coupling laser desorption with plasma-based SICRIT ionization improves ionization efficiency and signal stability under atmospheric conditions. The technique offers compatibility with various mass spectrometers and minimal sample preparation. Limitations include dependence on ablation parameters and limited coverage of large biomolecules. SICRIT imaging is an emerging approach promising enhanced molecular coverage and flexible ambient-MSI workflows.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin and colleagues stated that doses of 1 to 3 mg orally produced clear threshold effects and that it was active at a dose of slightly more than twice that of DOM. It was stated that 10 mg DOBU was required to produce hallucinogenic effects. The drug's duration was listed as "very long". There was limited investigation of its qualitative effects. However, in PiHKAL, at the assessed doses of 2.2 mg and 2.8 mg, it was described as producing paresthesia and difficulty sleeping with few other effects. The effects of higher doses of DOBU have not been described beyond them producing hallucinogenic effects.
December 15 – An outbreak of more than 10 wildfires begins in the state of Kansas, scorching an area of more than 163,000 acres (66,000 ha) on the first day they were first reported due to gusty winds and dry grassland. The outbreak leaves the deaths of two people and injures three more. December 17 – The Ohio Department of Education concludes their investigation into the Bishop Sycamore High School scandal, labeling the school as a scam. December 20 – COVID-19 pandemic: The CDC reports that Deltacron hybrid variant is now pre-dominant strain in the US, which is combined with Delta and Omicron variants, accounting for three-quarters of cases. December 29 British socialite Ghislaine Maxwell is convicted in a federal court on five of six charges relating to her recruiting and trafficking young girls to be sexually abused by the late financier Jeffrey Epstein. COVID-19 pandemic: The U.S. breaks its single-day case record, with over 488,000 new infections, nearly doubling the highest number from the previous winter. December 30 – Tens of thousands are evacuated as wildfires sweep through Boulder County, fanned by winds of up to 105 mph (169 km/h). The fires are the most destructive in Colorado's history.
It may consist of a single component or it may be a mixture of components. When the sample is treated in the course of an analysis, the phase or the phases containing the analytes of interest is/are referred to as the sample, whereas everything out of interest separated from the sample before or in the course of the analysis is referred to as waste. Solute – the sample components in partition chromatography. Solvent – any substance capable of solubilizing another substance, and especially the liquid mobile phase in liquid chromatography. Stationary phase – the substance fixed in place for the chromatography procedure. Examples include the silica layer in thin-layer chromatography Detector – the instrument used for qualitative and quantitative detection of analytes after separation. Chromatography is based on the concept of partition coefficient. Any solute partitions between two immiscible solvents. When one make one solvent immobile (by adsorption on a solid support matrix) and another mobile it results in most common applications of chromatography. If the matrix support, or stationary phase, is polar (e.g., cellulose, silica etc.) it is forward phase chromatography. Otherwise this technique is known as reversed phase, where a non-polar stationary phase (e.g., non-polar derivative of C-18) is used.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.